Livingston Group Asset Management CO operating as Southport Capital Management increased its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 79.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,449 shares of the biopharmaceutical company’s stock after acquiring an additional 5,512 shares during the period. Livingston Group Asset Management CO operating as Southport Capital Management’s holdings in Bristol-Myers Squibb were worth $763,000 at the end of the most recent reporting period.
A number of other large investors have also bought and sold shares of the stock. Bredin Investment LLC bought a new position in shares of Bristol-Myers Squibb in the fourth quarter worth approximately $1,937,000. Howard Capital Management lifted its stake in shares of Bristol-Myers Squibb by 0.5% in the fourth quarter. Howard Capital Management now owns 176,010 shares of the biopharmaceutical company’s stock worth $10,786,000 after buying an additional 804 shares in the last quarter. Cornerstone Financial Partners LLC bought a new position in shares of Bristol-Myers Squibb in the fourth quarter worth approximately $260,000. Cornerstone Investment Partners LLC lifted its stake in shares of Bristol-Myers Squibb by 100.0% in the fourth quarter. Cornerstone Investment Partners LLC now owns 19,168 shares of the biopharmaceutical company’s stock worth $1,175,000 after buying an additional 9,584 shares in the last quarter. Finally, Patten & Patten Inc. TN lifted its stake in shares of Bristol-Myers Squibb by 5.5% in the fourth quarter. Patten & Patten Inc. TN now owns 176,814 shares of the biopharmaceutical company’s stock worth $10,835,000 after buying an additional 9,251 shares in the last quarter. 69.82% of the stock is currently owned by institutional investors and hedge funds.
In other Bristol-Myers Squibb news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the sale, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at $585,033.24. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by corporate insiders.
Bristol-Myers Squibb Co (NYSE:BMY) opened at $67.35 on Wednesday. The company has a current ratio of 1.55, a quick ratio of 1.43 and a debt-to-equity ratio of 0.59. Bristol-Myers Squibb Co has a twelve month low of $51.56 and a twelve month high of $70.05. The firm has a market cap of $112,582.92, a P/E ratio of 22.91, a PEG ratio of 2.14 and a beta of 1.09.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The firm had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. During the same period in the previous year, the company earned $0.63 earnings per share. The firm’s quarterly revenue was up 3.9% on a year-over-year basis. analysts anticipate that Bristol-Myers Squibb Co will post 3.21 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Friday, January 5th were issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 2.38%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Thursday, January 4th. Bristol-Myers Squibb’s payout ratio is presently 271.19%.
WARNING: This piece of content was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2018/02/21/livingston-group-asset-management-co-operating-as-southport-capital-management-boosts-position-in-bristol-myers-squibb-co-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.